IFOSLIEVA 1 g contains Ifosfamide, an alkylating antineoplastic agent (nitrogen mustard derivative), supplied with Mesna. Ifosfamide causes DNA cross-linking, inhibiting DNA replication and leading to cancer cell death. Mesna is co-administered to prevent hemorrhagic cystitis by binding toxic uro-metabolites (acrolein) in the urinary tract.

Ifosfamide (with Mesna) is used in:

1. Soft Tissue Sarcomas

2. Osteosarcoma

3. Testicular Cancer (salvage regimens)

4. Non-Hodgkin’s Lymphoma

5. Ewing’s Sarcoma

6. Germ Cell Tumors

Common side effects:

•  Myelosuppression (neutropenia, thrombocytopenia)

•  Nausea, vomiting

•  Alopecia

•  Fatigue

Specific toxicities:

•  Hemorrhagic cystitis (prevented by Mesna + hydration)

•  Neurotoxicity (confusion, somnolence, hallucinations)

•  Nephrotoxicity

Serious side effects:

•  Severe infections

•  Electrolyte imbalance

•  Encephalopathy (rare but serious)

Close monitoring of CBC, renal function, electrolytes, and mental status is essential.

Dosage depends on regimen, indication, and patient factors.

Common dosing:

•  1.2–2 g/m²/day IV for 3–5 days

•  Given with adequate hydration

•  Mesna dose = 60–100% of Ifosfamide dose, divided and timed with infusion

1 g vial allows flexible dose calculation based on BSA.

NOTE: This medicine should be taken only under a doctor’s supervision.